Log in

Relevant bibliographies by topics / MRNA technology / Journal articles

To see the other types of publications on this topic, follow the link: MRNA technology.

Journal articles on the topic 'MRNA technology'

Author: Grafiati

Published: 7 June 2025

Last updated: 17 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'MRNA technology.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Li, Y., X. Zhou, M. A. R. St. John, and D. T. W. Wong. "RNA Profiling of Cell-free Saliva Using Microarray Technology." Journal of Dental Research 83, no. 3 (2004): 199–203. http://dx.doi.org/10.1177/154405910408300303.

Full text

Abstract:

Saliva, like other bodily fluids, has been used to monitor human health and disease. This study tests the hypothesis that informative human mRNA exists in cell-free saliva. If present, salivary mRNA may provide potential biomarkers to identify populations and patients at high risk for oral and systemic diseases. Unstimulated saliva was collected from ten normal subjects. RNA was isolated from the cell-free saliva supernatant and linearly amplified. High-density oligonucleotide microarrays were used to profile salivary mRNA. The results demonstrated that there are thousands of human mRNAs in ce

APA, Harvard, Vancouver, ISO, and other styles

2

Toniolo, Antonio, Giuseppe Maccari, and Giovanni Camussi. "mRNA Technology and Mucosal Immunization." Vaccines 12, no. 6 (2024): 670. http://dx.doi.org/10.3390/vaccines12060670.

Full text

Abstract:

Current mRNA vaccines are mainly administered via intramuscular injection, which induces good systemic immunity but limited mucosal immunity. Achieving mucosal immunity through mRNA vaccination could diminish pathogen replication at the entry site and reduce interhuman transmission. However, delivering mRNA vaccines to mucosae faces challenges like mRNA degradation, poor entry into cells, and reactogenicity. Encapsulating mRNA in extracellular vesicles may protect the mRNA and reduce reactogenicity, making mucosal mRNA vaccines possible. Plant-derived extracellular vesicles from edible fruits

APA, Harvard, Vancouver, ISO, and other styles

3

Provost, Patrick, Nicolas Derome, Christian Linard, Bernard Massie, and Jean Caron. "Potential Conscientious Objection to mRNA Technology as Preventive Treatment for COVID-19." International Journal of Vaccine Theory, Practice, and Research 2, no. 2 (2022): 445–54. http://dx.doi.org/10.56098/ijvtpr.v2i2.41.

Full text

Abstract:

In the context of mass vaccination campaigns, the most widely used vaccines in Western countries are based on messenger RNA (mRNA). Some countries have imposed mandatory vaccination and many others have required a vaccination passport to access public transportation and many activities, producing systemic discrimination, social exclusion, segregation, and stigmatization against non-vaccinated individuals. This paper aims to present several scientific uncertainties on which, conscientious objectors to mRNA injections as a preventive treatment for COVID-19, could rely. Scientific data are presen

APA, Harvard, Vancouver, ISO, and other styles

4

Liu, Yongbin, Dongfang Yu, Lingyi Huang, and Junhua Mai. "Abstract 4482: Development of a stable and efficient therapeutic mRNA cancer vaccine utilizing RNA-plex technology." Cancer Research 85, no. 8_Supplement_1 (2025): 4482. https://doi.org/10.1158/1538-7445.am2025-4482.

Full text

Abstract:

Abstract Background: Therapeutic mRNA vaccine is a promising approach for cancer immunotherapy. However, one of its major challenges is the inherent instability of mRNAs, as it is highly sensitive to ambient environments. Consequently, current mRNA vaccines require production, shipping, and storage at ultra-low temperatures, limiting their global application and increasing costs. Thus, enhancing mRNA stability is essential to develop stable mRNA-based therapeutic vaccines. Methods: In this study, we developed a novel mRNA stabilization technology termed "RNA-plex", which prevents mRNA from hyd

APA, Harvard, Vancouver, ISO, and other styles

5

Yılmaz, Engin. "Aşı Teknolojisinde Yeni Umutlar: mRNA Aşıları." Mikrobiyoloji Bulteni 55, no. 2 (2021): 265–84. http://dx.doi.org/10.5578/mb.20219912.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Le Page, Michael. "mRNA technology may treat stubborn diseases." New Scientist 253, no. 3367 (2022): 9. http://dx.doi.org/10.1016/s0262-4079(21)02292-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Pardi, Norbert, Michael J. Hogan, and Drew Weissman. "Recent advances in mRNA vaccine technology." Current Opinion in Immunology 65 (August 2020): 14–20. http://dx.doi.org/10.1016/j.coi.2020.01.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Fortner, Andra, and Octavian Bucur. "mRNA-based vaccine technology for HIV." Discoveries 10, no. 2 (2022): e150. http://dx.doi.org/10.15190/d.2022.9.

Full text

Abstract:

Human immunodeficiency virus (HIV) poses a major health problem around the globe, resulting in hundred-thousands of deaths from AIDS and over a million new infections annually. Although the standard treatment of HIV infection, antiretroviral therapy, has proven effective in preventing HIV transmission, it is unsuitable for worldwide use due to its substantial costs and frequent adverse effects. Besides promoting HIV/AIDS awareness through education, there is hardly an alternative for inhibiting the spread of the disease. One promising approach is the development of an HIV vaccine. Unfortunatel

APA, Harvard, Vancouver, ISO, and other styles

9

Oloruntimehin, Sola, Florence Akinyi, Michael Paul, and Olumuyiwa Ariyo. "mRNA Vaccine Technology Beyond COVID-19." Vaccines 13, no. 6 (2025): 601. https://doi.org/10.3390/vaccines13060601.

Full text

Abstract:

Background/Objectives: Since their approval in early 2020, mRNA vaccines have gained significant attention since the COVID-19 pandemic as a potential therapeutic approach to tackle several infectious diseases. This article aims to review the current state of mRNA vaccine technology and its use against other diseases. Methods: To obtain accurate and reliable data, we carefully searched the clinicaltrial.gov and individual companies’ websites for current ongoing clinical trials reports. Also, we accessed different NCBI databases for recent articles or reports of clinical trials, innovative desig

APA, Harvard, Vancouver, ISO, and other styles

10

Şahiner, Fatih, and İsmail Selçuk Aygar. "A New Era in Vaccine Technology: mRNA-Based Vaccine Design." Journal of Molecular Virology and Immunology 1, no. 3 (2021): 9–17. https://doi.org/10.46683/jmvi.2020.15.

Full text

Abstract:

<strong>Özet</strong> Messenger RNA (mRNA) teknolojisi hem genetik hastalıkların ve kanserlerin tedavisinde (terapötik kanser aşıları) hem de enfeksiyöz hastalıkların yayılımının önlenmesinde gelecek vaat eden yeni nesil bir yaklaşımı temsil eder. mRNA aşı sistemlerinin temel mantığı istenilen bir proteinin viral bir enfeksiyonu taklit ederek vücutta üretilmesini sağlamak ve onun işlevlerinden yararlanmaktır. DNA temelli sistemlerden ve viral vektörlerden farklı olarak üretilmek istenilen proteine ait genetik kodu taşıyan mRNA molekülleri ikinci bir

APA, Harvard, Vancouver, ISO, and other styles

11

Zhou, Ying, Zhaoru Wu, Yibo Wang, et al. "Advances and Challenges in mRNA Vaccine Technology." Proceedings of Anticancer Research 9, no. 2 (2025): 27–42. https://doi.org/10.26689/par.v9i2.10067.

Full text

Abstract:

Since the outbreak of COVID-19, mRNA vaccine technology has achieved groundbreaking advancements. Characterized by its high safety profile and potent immune activation capabilities, this technology has demonstrated significant potential in the prevention of infectious diseases and cancer therapeutics, marking a new milestone in vaccine development. This review focuses on three key aspects—molecular design, delivery systems, and immunological mechanisms—providing a comprehensive analysis of structural optimization strategies, delivery methodologies, and immune modulation approaches for mRNA vac

APA, Harvard, Vancouver, ISO, and other styles

12

Turner-Bridger, Benita, Maximillian Jakobs, Leila Muresan та ін. "Single-molecule analysis of endogenous β-actin mRNA trafficking reveals a mechanism for compartmentalized mRNA localization in axons". Proceedings of the National Academy of Sciences 115, № 41 (2018): E9697—E9706. http://dx.doi.org/10.1073/pnas.1806189115.

Full text

Abstract:

During embryonic nervous system assembly, mRNA localization is precisely regulated in growing axons, affording subcellular autonomy by allowing controlled protein expression in space and time. Different sets of mRNAs exhibit different localization patterns across the axon. However, little is known about how mRNAs move in axons or how these patterns are generated. Here, we couple molecular beacon technology with highly inclined and laminated optical sheet microscopy to image single molecules of identified endogenous mRNA in growing axons. By combining quantitative single-molecule imaging with b

APA, Harvard, Vancouver, ISO, and other styles

13

Eralp, Yesim. "Application of mRNA Technology in Cancer Therapeutics." Vaccines 10, no. 8 (2022): 1262. http://dx.doi.org/10.3390/vaccines10081262.

Full text

Abstract:

mRNA-based therapeutics pose as promising treatment strategies for cancer immunotherapy. Improvements in materials and technology of delivery systems have helped to overcome major obstacles in generating a sufficient immune response required to fight a specific type of cancer. Several in vivo models and early clinical studies have suggested that various mRNA treatment platforms can induce cancer-specific cytolytic activity, leading to numerous clinical trials to determine the optimal method of combinations and sequencing with already established agents in cancer treatment. Nevertheless, furthe

APA, Harvard, Vancouver, ISO, and other styles

14

Schlake, Thomas, Andreas Thess, Moritz Thran, and Ingo Jordan. "mRNA as novel technology for passive immunotherapy." Cellular and Molecular Life Sciences 76, no. 2 (2018): 301–28. http://dx.doi.org/10.1007/s00018-018-2935-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Garrido, Nicolás, Sandra García-Herrero, and Marcos Meseguer. "Assessment of sperm using mRNA microarray technology." Fertility and Sterility 99, no. 4 (2013): 1008–22. http://dx.doi.org/10.1016/j.fertnstert.2013.02.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Miliotou, Androulla N., Sofia K. Georgiou-Siafis, Charikleia Ntenti, Ioannis S. Pappas, and Lefkothea C. Papadopoulou. "Recruiting In Vitro Transcribed mRNA against Cancer Immunotherapy: A Contemporary Appraisal of the Current Landscape." Current Issues in Molecular Biology 45, no. 11 (2023): 9181–214. http://dx.doi.org/10.3390/cimb45110576.

Full text

Abstract:

Over 100 innovative in vitro transcribed (IVT)-mRNAs are presently undergoing clinical trials, with a projected substantial impact on the pharmaceutical market in the near future. Τhe idea behind this is that after the successful cellular internalization of IVT-mRNAs, they are subsequently translated into proteins with therapeutic or prophylactic relevance. Simultaneously, cancer immunotherapy employs diverse strategies to mobilize the immune system in the battle against cancer. Therefore, in this review, the fundamental principles of IVT-mRNA to its recruitment in cancer immunotherapy, are di

APA, Harvard, Vancouver, ISO, and other styles

17

Dahl, Lars Ole Sti, Sjoerd Hak, Stine Braaen, et al. "Implementation of mRNA–Lipid Nanoparticle Technology in Atlantic Salmon (Salmo salar)." Vaccines 12, no. 7 (2024): 788. http://dx.doi.org/10.3390/vaccines12070788.

Full text

Abstract:

Background: This study was conducted to investigate whether mRNA vaccine technology could be adapted for the ectothermic vertebrate Atlantic salmon (Salmo salar). Lipid nanoparticle (LNP) technology has been developed and optimized for mRNA vaccines in mammals, stabilizing mRNA and facilitating its delivery into cells. However, its utility at the temperatures and specific biological environments present in ectotherms remains unclear. In addition, it is unknown if modified mRNA containing non-canonical nucleotides can correctly translate in salmonid cells. Methods: We used an mRNA transcript co

APA, Harvard, Vancouver, ISO, and other styles

18

Volkova, Oxana A., Yury V. Kondrakhin, Ivan S. Yevshin, Tagir F. Valeev, and Ruslan N. Sharipov. "Assessment of translational importance of mammalian mRNA sequence features based on Ribo-Seq and mRNA-Seq data." Journal of Bioinformatics and Computational Biology 14, no. 02 (2016): 1641006. http://dx.doi.org/10.1142/s0219720016410067.

Full text

Abstract:

Ribosome profiling technology (Ribo-Seq) allowed to highlight more details of mRNA translation in cell and get additional information on importance of mRNA sequence features for this process. Application of translation inhibitors like harringtonine and cycloheximide along with mRNA-Seq technique helped to assess such important characteristic as translation efficiency. We assessed the translational importance of features of mRNA sequences with the help of statistical analysis of Ribo-Seq and mRNA-Seq data. Translationally important features known from literature as well as proposed by the autho

APA, Harvard, Vancouver, ISO, and other styles

19

Plotnikova, Marina A., Ekaterina A. Romanovskaya-Romanko, Anastasia A. Pulkina, Marina A. Shuklina, Anna-Polina S. Shurygina, and Sergey A. Klotchenko. "In Vitro Evaluation of the Antiviral Properties of Exogenous mRNA Encoding the Human MxA Protein." Microbiology Research 16, no. 2 (2025): 32. https://doi.org/10.3390/microbiolres16020032.

Full text

Abstract:

MxA is a cytoplasmic protein induced in human cells exposed to type I and III interferons. It can inhibit various viruses, including influenza A, by blocking the early steps of the viral replication cycle. The rapid advancement of mRNA-based technology has allowed us to evaluate the antiviral activity of MxA-mRNA, encoding intracellular MxA protein, and explore its potential as a therapeutic agent. In this study, we used in vitro transfection methods to obtain functional, mature MxA-mRNA and evaluate its activity within cells. We also observed an undesirable cellular response to transfection w

APA, Harvard, Vancouver, ISO, and other styles

20

Litvinova, V. R., A. P. Rudometov, L. I. Karpenko, and A. A. Ilyichev. "mRNA-Vaccine Platform: Features of Obtaining and Delivery of mRNA." Биоорганическая химия 49, no. 2 (2023): 134–52. http://dx.doi.org/10.31857/s013234232302015x.

Full text

Abstract:

Vaccination is the most effective way to prevent infectious diseases. One new approach to vaccine development is mRNA-based vaccines, which have a number of very useful advantages over other types of vaccines. As the mRNA only encodes the target antigen, there is no potential risk of infection, as would be the case with an attenuated or inactivated pathogen. The principle of mRNA vaccines’ action is function in the cytosol of the cell; due to this the probability of mRNA integration into the host genome is extremely low. mRNA vaccines are able to induce specific cellular and humoral immune res

APA, Harvard, Vancouver, ISO, and other styles

21

Skerritt, John H., Carolyn Tucek-Szabo, Brett Sutton, and Terry Nolan. "The Platform Technology Approach to mRNA Product Development and Regulation." Vaccines 12, no. 5 (2024): 528. http://dx.doi.org/10.3390/vaccines12050528.

Full text

Abstract:

mRNA-lipid nanoparticle (LNP) medicinal products can be considered a platform technology because the development process is similar for different diseases and conditions, with similar noncoding mRNA sequences and lipid nanoparticles and essentially unchanged manufacturing and analytical methods often utilised for different products. It is critical not to lose the momentum built using the platform approach during the development, regulatory approval and rollout of vaccines for SARS-CoV-2 and its variants. This review proposes a set of modifications to existing regulatory requirements for mRNA p

APA, Harvard, Vancouver, ISO, and other styles

22

Feinberg, Mark. "Leveraging mRNA technology to accelerate HIV vaccine development." Vaccine Insights 02, no. 03 (2023): 87–92. http://dx.doi.org/10.18609/vac.2023.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Kirby, Tony. "mRNA vaccine technology for a multivalent flu vaccine." Lancet Infectious Diseases 23, no. 2 (2023): 157. http://dx.doi.org/10.1016/s1473-3099(23)00013-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Chen, Zhi, Jingpeng Zhou, Xiaolong Wang, et al. "Screening candidate microR-15a- IRAK2 regulatory pairs for predicting the response to Staphylococcus aureus-induced mastitis in dairy cows." Journal of Dairy Research 86, no. 4 (2019): 425–31. http://dx.doi.org/10.1017/s0022029919000785.

Full text

Abstract:

AbstractWe established a mastitis model using exogenous infection of the mammary gland of Chinese Holstein cows with Staphylococcus aureus and extracted total RNA from S. aureus-infected and healthy mammary quarters. Differential expression of genes due to mastitis was evaluated using Affymetrix technology and results revealed a total of 1230 differentially expressed mRNAs. A subset of affected genes was verified via Q-PCR and pathway analysis. In addition, Solexa high-throughput sequencing technology was used to analyze profiles of miRNA in infected and healthy quarters. These analyses reveal

APA, Harvard, Vancouver, ISO, and other styles

25

Gerold, Megan N., Evan Toth, Rebecca H. Blair, et al. "Analytical Performance of a Multiplexed Microarray Assay for Rapid Identification and Quantification of a Multivalent mRNA Vaccine." Vaccines 12, no. 10 (2024): 1144. http://dx.doi.org/10.3390/vaccines12101144.

Full text

Abstract:

mRNA vaccines were highly effective in response to the COVID-19 pandemic, making them an attractive platform to address cancers and other infectious diseases. Many new mRNA vaccines in development are multivalent, which represents a difficulty for the standard assays commonly used to characterize the critical quality attributes of monovalent formulations. Here, we present a multiplexed analytical tool with nucleic acid microarray technology using the VaxArray platform that measures the identity and quantity of mono- and multivalent mixtures of naked mRNA and mRNA encapsulated in lipid nanopart

APA, Harvard, Vancouver, ISO, and other styles

26

Floudas, Charalampos S., Siranush Sarkizova, Michele Ceccarelli, and Wei Zheng. "Leveraging mRNA technology for antigen based immuno-oncology therapies." Journal for ImmunoTherapy of Cancer 13, no. 1 (2025): e010569. https://doi.org/10.1136/jitc-2024-010569.

Full text

Abstract:

The application of messenger RNA (mRNA) technology in antigen-based immuno-oncology therapies represents a significant advancement in cancer treatment. Cancer vaccines are an effective combinatorial partner to sensitize the host immune system to the tumor and boost the efficacy of immune therapies. Selecting suitable tumor antigens is the key step to devising effective vaccinations and amplifying the immune response. Tumor neoantigens are de novo epitopes derived from somatic mutations, avoiding T-cell central tolerance of self-epitopes and inducing immune responses to tumors. The identificati

APA, Harvard, Vancouver, ISO, and other styles

27

Xian, He, Yue Zhang, Chengzhong Yu, and Yue Wang. "Nanobiotechnology-Enabled mRNA Stabilization." Pharmaceutics 15, no. 2 (2023): 620. http://dx.doi.org/10.3390/pharmaceutics15020620.

Full text

Abstract:

mRNA technology has attracted enormous interest due to its great therapeutic potential. Strategies that can stabilize fragile mRNA molecules are crucial for their widespread applications. There are numerous reviews on mRNA delivery, but few focus on the underlying causes of mRNA instability and how to tackle the instability issues. Herein, the recent progress in nanobiotechnology-enabled strategies for stabilizing mRNA and better delivery is reviewed. First, factors that destabilize mRNA are introduced. Second, nanobiotechnology-enabled strategies to stabilize mRNA molecules are reviewed, incl

APA, Harvard, Vancouver, ISO, and other styles

28

Lee, Sojin, Joon Young Park, Goo-Young Kim, et al. "708 Application of a novel mSENS drug delivery technology for mRNA therapeutics." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A750. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0708.

Full text

Abstract:

BackgroundSuccessful clinical translation of mRNA therapeutics requires an appropriate delivery strategy to overcome instability of mRNA and facilitate cellular uptake into the cells.1 Several lipid based nanoparticle approaches that encapsulate mRNA, notably lipid nanoparticle (LNP), have been developed, but their efficiency for delivery to certain target tissues and toxicity profiles still have room for improvement. The application of a novel polymer based nanoparticle technology platform, so called Stability Enhanced Nano Shells (SENS) for mRNA (mSENS) as a mRNA delivery platform for a canc

APA, Harvard, Vancouver, ISO, and other styles

29

Paczkowska, Anna, Karolina Hoffmann, Agata Andrzejczak, et al. "The Application of mRNA Technology for Vaccine Production—Current State of Knowledge." Vaccines 13, no. 4 (2025): 389. https://doi.org/10.3390/vaccines13040389.

Full text

Abstract:

Over the past 20 years, intensive research has been conducted on the development of therapeutic mRNA, leading to numerous discoveries that have enabled its use in therapy. The main achievements in this field include increasing mRNA stability, reducing its immunogenicity (i.e., its ability to trigger an immune response), and solving the challenge of delivering mRNA into cells—all to achieve a therapeutic effect. The aim of this study was to review the scientific literature on the use of mRNA technology in the production of vaccines. Various methods of applying mRNA technology that could potenti

APA, Harvard, Vancouver, ISO, and other styles

30

Starostina, E. V., L. F. Nizolenko, L. I. Karpenko, and A. A. Ilyichev. "Antitumor mRNA vaccines based on neoantigens." Siberian journal of oncology 23, no. 6 (2025): 149–58. https://doi.org/10.21294/1814-4861-2024-23-6-149-158.

Full text

Abstract:

Objective: to summarize the available data on clinical trials of vaccines based on mRNA encoding neoantigens. Material and Methods. Data were searched on https://classic.clinicaltrials.gov and https://pubmed.ncbi.nlm.nih.gov/, from January 2013 to May 2024 using the keywords “neoantigen” and “vaccine”, and the information on mRNA-based drugs was then selected. Of the 148 studies retrieved, 54 were selected to write a systematic review. Results. A bibliometric analysis of data in the field of therapeutic cancer vaccines from 2013 to 2024 showed that the majority of studies focused on mRNA vacci

APA, Harvard, Vancouver, ISO, and other styles

31

Moya-Ramírez, Ignacio, Clement Bouton, Cleo Kontoravdi, and Karen Polizzi. "High resolution biosensor to test the capping level and integrity of mRNAs." Nucleic Acids Research 48, no. 22 (2020): e129-e129. http://dx.doi.org/10.1093/nar/gkaa955.

Full text

Abstract:

Abstract 5′ Cap structures are ubiquitous on eukaryotic mRNAs, essential for post-transcriptional processing, translation initiation and stability. Here we describe a biosensor designed to detect the presence of cap structures on mRNAs that is also sensitive to mRNA degradation, so uncapped or degraded mRNAs can be detected in a single step. The biosensor is based on a chimeric protein that combines the recognition and transduction roles in a single molecule. The main feature of this sensor is its simplicity, enabling semi-quantitative analyses of capping levels with minimal instrumentation. T

APA, Harvard, Vancouver, ISO, and other styles

32

Vidhyalakshmi R, Rajaganapathy K, Kowsika M, and Pratheeba G. "The Transformative Potential of mRNA Vaccines in Revolutionizing Vaccine Development And Therapeutic Applications." Journal of Pharma Insights and Research 2, no. 3 (2024): 080–87. http://dx.doi.org/10.69613/vpxx7e92.

Full text

Abstract:

Messenger RNA (mRNA) technology has emerged as a transformative force in the field of vaccine development and therapeutic applications, revolutionizing the landscape of modern medicine. This cutting-edge technology enables the rapid and flexible design of vaccines and therapeutics, unleashing a new era of personalized and targeted treatments. During the COVID-19 pandemic, mRNA vaccines demonstrated their immense potential by facilitating the swift development and deployment of highly effective vaccines against SARS-CoV-2, contributing significantly to the global response against the virus. Bey

APA, Harvard, Vancouver, ISO, and other styles

33

Liao, Wan-Lin, Wei-Chiao Wang, Wen-Chang Chang та Joseph T. Tseng. "The RNA-binding Protein HuR Stabilizes Cytosolic Phospholipase A2α mRNA under Interleukin-1β Treatment in Non-small Cell Lung Cancer A549 Cells". Journal of Biological Chemistry 286, № 41 (2011): 35499–508. http://dx.doi.org/10.1074/jbc.m111.263582.

Full text

Abstract:

The activation of cytosolic phospholipase A2α (cPLA2α) plays an important role in initiating the inflammatory response. The regulation of cPLA2α mRNA turnover has been proposed to control cPLA2α gene expression under cytokine and growth factor stimulation. However, the detailed mechanism is still unknown. In this report, we have demonstrated that the cPLA2α mRNA stability was increased under IL-1β treatment in A549 cells. By using EMSAs, HuR was identified as binding with the cPLA2α mRNA 3′-UTR, and the binding region was located at nucleotides 2716–2807, a fragment containing AUUUA flanked by

APA, Harvard, Vancouver, ISO, and other styles

34

Niazi, Sarfaraz K. "Affordable mRNA Novel Proteins, Recombinant Protein Conversions, and Biosimilars—Advice to Developers and Regulatory Agencies." Biomedicines 13, no. 1 (2025): 97. https://doi.org/10.3390/biomedicines13010097.

Full text

Abstract:

mRNA technology can replace the expensive recombinant technology for every type of protein, making biological drugs more affordable. It can also expedite the entry of new biological drugs, and copies of approved mRNA products can be treated as generic or biosimilar products due to their chemical nature. The introduction of hundreds of new protein drugs have been blocked due to the high cost of recombinant development. The low CAPEX and OPEX associated with mRNA technology bring it within the reach of developing countries that are currently deprived of life-saving biological drugs. In this pape

APA, Harvard, Vancouver, ISO, and other styles

35

R, Palacios-Castrillo. "The Science and the Potential Dangers behind RNA-based Vaccine Technology." Virology & Immunology Journal 7, no. 4 (2023): 1–3. http://dx.doi.org/10.23880/vij-16000333.

Full text

Abstract:

The differences between natural mRNA and laboratory modified RNA (Mod-RNA) are remarked. The therapeutic applications of ModRNA in humans have been showing serious challenges and dangers. Considering these concerns, it's important to address the safety of mass vaccination programs that administer gene therapy treatments to healthy individuals. Robust risk-benefit analysis and long-term surveillance in preclinical and clinical trials are essential before implementing any new technology on a wide scale. Despite everything we were told, the RNA-based COVID-19 injections were made with modified RN

APA, Harvard, Vancouver, ISO, and other styles

36

Esprit, Arthur, Wout de Mey, Rajendra Bahadur Shahi, Kris Thielemans, Lorenzo Franceschini, and Karine Breckpot. "Neo-Antigen mRNA Vaccines." Vaccines 8, no. 4 (2020): 776. http://dx.doi.org/10.3390/vaccines8040776.

Full text

Abstract:

The interest in therapeutic cancer vaccines has caught enormous attention in recent years due to several breakthroughs in cancer research, among which the finding that successful checkpoint blockade treatments reinvigorate neo-antigen-specific T cells and that successful adoptive cell therapies are directed towards neo-antigens. Neo-antigens are cancer-specific antigens, which develop from somatic mutations in the cancer cell genome that can be highly immunogenic and are not subjected to central tolerance. As the majority of neo-antigens are unique to each patient’s cancer, a vaccine technolog

APA, Harvard, Vancouver, ISO, and other styles

37

Jahnz-Różyk, Karina, and Ewa Więsik-Szewczyk. "Application of mRNA technology in vaccines against pandemic pathogens - present and future." Journal of Health Policy & Outcomes Research, no. 3 (August 31, 2022): 27–34. http://dx.doi.org/10.7365/jhpor.2021.3.3.

Full text

Abstract:

MRNA vaccines have become an important resource in the fight against the COVID-19 pandemic, caused by the SARS-Cov2 virus. This article presents the history of vaccines against various pathogens, as well as the history of mRNA technology and its current application. It also points to the development of mRNA vaccines in the near future. This technology appears to be a milestone in global vaccinology.

APA, Harvard, Vancouver, ISO, and other styles

38

Meguro, K., K. Igarashi, M. Yamamoto, H. Fujita, and S. Sassa. "The role of the erythroid-specific delta-aminolevulinate synthase gene expression in erythroid heme synthesis." Blood 86, no. 3 (1995): 940–48. http://dx.doi.org/10.1182/blood.v86.3.940.940.

Full text

Abstract:

Abstract Using antisense technology, the effects of suppressed gene expression of the erythroid-specific delta-aminolevulinate (ALA) synthase (ALAS-E) on heme synthesis, expression of mRNAs encoding an erythroid-specific transcription factor NF-E2, other heme pathway enzymes, and beta-globin were examined in murine erythroleukemia (MEL) cells. In MEL cells in which an antisense ALAS-E RNA was expressed (AS clone), sense ALAS-E mRNA levels in both untreated and dimethylsulfoxide (DMSO)-treated cells were decreased compared with their respective controls. Heme synthesis in AS clones was decrease

APA, Harvard, Vancouver, ISO, and other styles

39

Meguro, K., K. Igarashi, M. Yamamoto, H. Fujita, and S. Sassa. "The role of the erythroid-specific delta-aminolevulinate synthase gene expression in erythroid heme synthesis." Blood 86, no. 3 (1995): 940–48. http://dx.doi.org/10.1182/blood.v86.3.940.bloodjournal863940.

Full text

Abstract:

Using antisense technology, the effects of suppressed gene expression of the erythroid-specific delta-aminolevulinate (ALA) synthase (ALAS-E) on heme synthesis, expression of mRNAs encoding an erythroid-specific transcription factor NF-E2, other heme pathway enzymes, and beta-globin were examined in murine erythroleukemia (MEL) cells. In MEL cells in which an antisense ALAS-E RNA was expressed (AS clone), sense ALAS-E mRNA levels in both untreated and dimethylsulfoxide (DMSO)-treated cells were decreased compared with their respective controls. Heme synthesis in AS clones was decreased in prop

APA, Harvard, Vancouver, ISO, and other styles

40

Jia, Kaining, Xiaocang Ren, Yuee Liu, and Jiawei Wang. "Screening and Biological Function Analysis of miRNA and mRNA Related to Lung Adenocarcinoma Based on Bioinformatics Technology." Journal of Oncology 2022 (August 31, 2022): 1–13. http://dx.doi.org/10.1155/2022/4339391.

Full text

Abstract:

Objective. To screen the differentially expressed miRNAs (DEMs) and the differentially expressed gene mRNAs (DEGs) in lung adenocarcinoma (LUAD) from the TCGA database and to explore the relationship between miRNAs and the prognosis of lung adenocarcinoma and their biological functions. Methods. The RNA-seq and miRNA-seq data of lung adenocarcinoma samples were downloaded from the TCGA database for analysis, and the R program was used to screen for differentially expressed miRNAs and mRNAs. Then, the molecular functions, biological processes, cellular components, and signaling pathways involve

APA, Harvard, Vancouver, ISO, and other styles

41

Xie, Wen, Baiping Chen, and John Wong. "Publisher Correction: Evolution of the market for mRNA technology." Nature Reviews Drug Discovery 20, no. 11 (2021): 880. http://dx.doi.org/10.1038/s41573-021-00326-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Khormi, Ali Hassan Ibrahim, Raied Mohammad Mosa Qohal, Abdulrahman Yahya Ahmed Masrai, et al. "Emerging Trends in mRNA Vaccine Technology: Beyond Infectious Diseases." Egyptian Journal of Chemistry 67, no. 13 (2024): 1567–74. https://doi.org/10.21608/ejchem.2024.337883.10838.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Watts, Geoff. "Petro Terblanche: developing an mRNA technology hub in Africa." Lancet 401, no. 10393 (2023): 2030. http://dx.doi.org/10.1016/s0140-6736(23)01186-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Nogrady, Bianca. "mRNA technology helps reinvigorate the hunt for cancer vaccines." Nature 640, no. 8060 (2025): S54—S56. https://doi.org/10.1038/d41586-025-01151-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Silva, Heslley. "mRNA Technology in Modern Medicine: Review and Future Prospects." Clinical and Molecular Epidemiology 2 (January 17, 2025): 1. https://doi.org/10.53964/cme.2025001.

Full text

Abstract:

Messenger RNA (mRNA) technology has revolutionized modern medicine, particularly in developing vaccines and gene therapies. While its prominence soared during the COVID-19 pandemic, its foundation was built on decades of meticulous research. This review explores the historical evolution of mRNA technology, its stabilization and delivery breakthroughs, and its applications in combating infectious diseases, cancer, and genetic disorders. The study utilized a systematic search of peer-reviewed articles from leading databases such as PubMed and Scopus, focusing on advancements and clinical applica

APA, Harvard, Vancouver, ISO, and other styles

46

Semple, Sean C., Robert Leone, Christopher J. Barbosa, Ying K. Tam, and Paulo J. C. Lin. "Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics." Pharmaceutics 14, no. 2 (2022): 398. http://dx.doi.org/10.3390/pharmaceutics14020398.

Full text

Abstract:

The world raced to develop vaccines to protect against the rapid spread of SARS-CoV-2 infection upon the recognition of COVID-19 as a global pandemic. A broad spectrum of candidates was evaluated, with mRNA-based vaccines emerging as leaders due to how quickly they were available for emergency use while providing a high level of efficacy. As a modular technology, the mRNA-based vaccines benefitted from decades of advancements in both mRNA and delivery technology prior to the current global pandemic. The fundamental lessons of the utility of mRNA as a therapeutic were pioneered by Dr. Katalin K

APA, Harvard, Vancouver, ISO, and other styles

47

Kaya, Çağlar, and Tolga Sarıyer. "Gene Silencing RNAi Technology: Uses in Plants." JOURNAL OF GLOBAL CLIMATE CHANGE 1, no. 1 (2022): 7–14. http://dx.doi.org/10.56768/jytp.1.1.02.

Full text

Abstract:

Ensuring sustainable food production in national and global area depends on the determination of plant species and varieties that can survive under the influence of various stress factors that may occur due to global climate changes and other factors that adversely limit growth and development, and depends on the protection and development of existing ones. It is important to develop new plant varieties that are resistant to abiotic stress factors that have occurred as a result of global climate changes. At this point, modern biotechnological methods have been widely needed in plant breeding i

APA, Harvard, Vancouver, ISO, and other styles

48

Perenkov, Alexey D., Alena D. Sergeeva, Maria V. Vedunova, and Dmitri V. Krysko. "In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future." Vaccines 11, no. 10 (2023): 1600. http://dx.doi.org/10.3390/vaccines11101600.

Full text

Abstract:

mRNA was discovered in 1961, but it was not used as a vaccine until after three decades. Recently, the development of mRNA vaccine technology gained great impetus from the pursuit of vaccines against COVID-19. To improve the properties of RNA vaccines, and primarily their circulation time, self-amplifying mRNA and trans-amplifying mRNA were developed. A separate branch of mRNA technology is circular RNA vaccines, which were developed with the discovery of the possibility of translation on their protein matrix. Circular RNA has several advantages over mRNA vaccines and is considered a fairly pr

APA, Harvard, Vancouver, ISO, and other styles

49

Ilyichev, A. A., L. A. Orlova, S. V. Sharabrin, and L. I. Karpenko. "mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development." Vavilov Journal of Genetics and Breeding 24, no. 7 (2020): 802–7. http://dx.doi.org/10.18699/vj20.676.

Full text

Abstract:

After the genome sequence of SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2) was published and the number of infected people began to increase rapidly, many global companies began to develop a vaccine. Almost all known approaches to vaccine design were applied for this purpose, including inactivated viruses, mRNA and DNA-vaccines, vaccines based on various viral vectors, synthetically generated peptides and recombinant proteins produced in cells of insects and mammals. This review considers one of the promising vaccine platforms based on messenger RNA. Until recent years,

APA, Harvard, Vancouver, ISO, and other styles

50

Campbell, W. G., S. E. Gordon, C. J. Carlson, J. S. Pattison, M. T. Hamilton, and F. W. Booth. "Differential global gene expression in red and white skeletal muscle." American Journal of Physiology-Cell Physiology 280, no. 4 (2001): C763—C768. http://dx.doi.org/10.1152/ajpcell.2001.280.4.c763.

Full text

Abstract:

The differences in gene expression among the fiber types of skeletal muscle have long fascinated scientists, but for the most part, previous experiments have only reported differences of one or two genes at a time. The evolving technology of global mRNA expression analysis was employed to determine the potential differential expression of ∼3,000 mRNAs between the white quad (white muscle) and the red soleus muscle (mixed red muscle) of female ICR mice (30–35 g). Microarray analysis identified 49 mRNA sequences that were differentially expressed between white and mixed red skeletal muscle, incl

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!